8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes

Similar documents
Antonio Colombo. Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy. Miracor Symposium. Speaker: 15. Parigi: May 16-19, 2017

Mechanics of Cath Lab Support Devices

Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO)

Assist Devices in STEMI- Intra-aortic Balloon Pump

Mechanics of Cath Lab Support Devices

Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California

Management of Acute Shock and Right Ventricular Failure

Rationale for Prophylactic Support During Percutaneous Coronary Intervention

Introduction to Acute Mechanical Circulatory Support

Unprotected LM intervention

Case - Advanced HF and Shock (INTERMACS 1)

Rationale for Left Ventricular Support During Percutaneous Coronary Intervention

When Aspiration Thrombectomy Does Not Work? A A R O N W O N G N A T I O N A L H E A R T C E N T R E S I N G A P O R E

ΑΙΤΙΑ ΕΙΣΑΓΩΓΗΣ ΓΙΑ ΝΟΣΗΛΕΙΑ ΑΝΔΡΑΣ

Extra Corporeal Life Support for Acute Heart failure

Management of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist

Percutaneous Mechanical Circulatory Support for Cardiogenic Shock. 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI

Mechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research

Alex versus Xience Registry Preliminary report

LM stenting - Cypher

The Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize

Who is the high risk patient?

ST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do?

Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )

ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April Session: Left mains & bifurcation intervention

What do the guidelines say?

Percutaneous Mechanical Circulatory Support Devices

Rhondalyn C. McLean. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume VII, A. Study Purpose and Rationale

Acute Mechanical Circulatory Support Right Ventricular Support Devices

Circulatory Support: From IABP to LVAD

Echo assessment of patients with an ECMO device

Ventricular Assisting Devices in the Cathlab. Unrestricted

Cardiogenic Shock. Carlos Cafri,, MD

Bridging With Percutaneous Devices: Tandem Heart and Impella

STEMI ST Elevation Myocardial Infarction

Impella Ins & Outs. CarVasz November :45 12:15

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes

Useful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication vs Benefit? Mortality? Morbidity?

I Was Too Late With Device Placement

J. Schwitter, MD, FESC Section of Cardiology

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Cardiologic history. Anamnesis. Female BD Risk factors HTN, DM, Dyslipidaemia. Cardiologic Long history. Last admission Heart failure

Mechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017

Focus on the role of Catheter Ablation: Simple cases Intermediate level Difficult cases (and patients) Impossible (almost )

Case Presentation #1

Cardiogenic Shock Protocol

EACTS Adult Cardiac Database

Ischemic Ventricular Septal Rupture

How to do Primary Angioplasty. - Patients with Cardiogenic Shock

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

To ECMO Or Not To ECMO Challenges of venous arterial ECMO. Dr Emily Granger St Vincent s Hospital Darlinghurst NSW

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Recovering Hearts. Saving Lives.

DECLARATION OF CONFLICT OF INTEREST

FFR vs icecg in Coronary Bifurcations FIESTA ClinicalTrials.gov Identifier: NCT

The Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

Detailed Order Request Checklists for Cardiology

Mechanical Cardiac Support and Cardiac Transplant: The Role for Echocardiography

New Therapies for the Heart Patient. Wilson They said "There's nothing more that can be done." Robert Federici MD, Presbyterian Heart

Case Report Treatment of a Distal Left Main Trifurcation Supported by the TandemHeartì Left Ventricular Assist Device

Ted Feldman, M.D., MSCAI FACC FESC

Matching Patient and Pump in the New Era of Percutaneous Mechanical Circulatory Support

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

Investigational Device only in the U.S. Not available for sale in the U.S. ACCESS EU European Society of Cardiology

Bifurcation stenting with BVS

Right Ventricular Failure: Prediction, Prevention and Treatment

Complications of Acute Myocardial Infarction

A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD

Insight from the CACTUS trial Coronary Bifurcation Application of the Crush

Acute heart failure: ECMO Cardiology & Vascular Medicine 2012

The majority of patients with cardiomyopathy

Cardiac Care Network of Ontario

Αγγειοπλαστική σε Nόσο Στελέχους: Που βρισκόμαστε. Βάιος Τζίφος Δ/ντής Τμήματος Επεμβατικής Καρδιολογίας Τομέας Καρδιάς Ερρίκος Ντυνάν Hospital Center

New York Valves Patient focused evidence-based approach. New York City: 6 December Antonio Colombo

LV Distension and ECLS Lungs

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia

CABG for ischemic cardiomyopathy, post myocardial infarction and cardiogenic shock

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION

Joint Congress PAFCIC Complex PCI meeting

Counterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece

Side Branch Occlusion

Mitigating Operator Risk in Complex Interventional Procedures. Tanveer Rab, MD, FACC Ajay Kirtane, MD, FACC Prashant Kaul, MD, FACC

Coronary Artery Perforation Angioplasty Summit Seoul April 30, 2005

Understanding the Pediatric Ventricular Assist Device

Cardiogenic Shock in Acute MI

Which mechanical assistance for cardiogenic shock?

Out-of-hospital Cardiac Arrest. Franz R. Eberli MD, FESC, FAHA Cardiology Triemli Hospital Zurich, Switzerland

Percutaneous Intervention of Unprotected Left Main Disease

Cath Lab Essentials: Basic Hemodynamics for the Cath Lab and ICU

ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries

Acute Myocardial Infarction Complicated by Cardiogenic Shock

Guideline compliance, utilization trends

Coronary angiography and PCI

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

ECMELLA. Associate Prof. Dirk Westermann, MD, PhD. Department of General and Interventional Cardiology Hamburg, Germany. Department of Medicine

Cardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands

STEMI and Cardiogenic Shock. The rules and solution. Dave Kettles St Dominics and Frere Hospitals East London ZA

Severity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root

Transcription:

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 OSPEDALE Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy

Nothing to disclose

Interventional Cardiology Unit, San Raffaele Scientific Institute Milan, Italy CASE SUMMARY Patient Demographics Age: 75 year old Gender: male Clinical Presentation - Acute Pulmonary Oedema. Medical History - Hypertension, dyslipidemia, familiar history of CAD - Previous hemorrhagic stroke in 1990 - February 2016 VTE on OAC. Echocardiography - EF 20% with apical aneurysm and spontaneous echocontrast. - IM ++. - RV dysfunction, PAPs 30 mmhg

Pre-procedural Echocardiogram OSPEDALE EF 25% Increased LV filling pressure

CORONARY ANGIOGRAM OSPEDALE Severe and calcified three vessels disease involving LM

CORONARY ANGIOGRAM OSPEDALE CTO of ostial RCA with Rentrop II from LAD

STRATEGY OSPEDALE Double femoral access LV support with Impella 2.5 Distal Circumflex treatment with Rotablator application Proximal LAD preparation with Rotablator application LM Bifurcation treatment IVUS evaluation

POSITIONING IMPELLA 2.5 OSPEDALE TIP: use of Lunderqvist wire to support device advance through tortuous Aorta

POSITIONING IMPELLA 2.5 OSPEDALE

Distal Circumflex treatment OSPEDALE Rotablator application (1.5 burr)

Proximal LAD preparation OSPEDALE Rotablator application (1.5 burr)

LM Treatment: minicrush OSPEDALE Crushing & Kissing

IVUS evaluation to optimize PCI: LAD evaluation OSPEDALE 65 4 3 2 1 2 1 Dissection 6 5 4 3 Ao LMT MSA 12.2mm 2 CX LAD MSA 8.8mm 2

Final angiographic result OSPEDALE

The incidence of cardiogenic shock has been declining from 7% in 1990 to 5% presently Current hospital mortality 5% Left main and triple vessel disease are the main offenders (Shock Trial, JACC 2000) Important predictors of outcome are: LV ejection fraction and degree of mitral regurgitation (Circ. 2003)

CO increase: 0.5 1 L/min Increases MAP Reduces LVEDP Increases coronary perfusion Sheath size: 7-8 F Easy to be implanted but minimal Hemodynamic Support Contraindicated with severe AR 19

IABP-Shock Trial; NEJM 2012 600 pts. randomized to IAPB versus supportive therapy 30 days mortality IABP: 39.7% Standard therapy: 41.3%

Active forward flow and LV unloading Impella 2.5: 12 F insertion sheath Impella CP, 4 lt/min: 14 F insertion sheath Impella 5 lt/min: 21 F insertion sheath Impella RP for RV support, 4 lt/min: 22 F insertion sheath

25 patients Impella 2.5 provides better haemodynamic support than IABP but no difference in mortality

48 patients No difference in 30 day mortality

3 Studies Survival benefit in Early Impella (During PCI) vs Late Impella (after PCI)

Selective RV Unloading CO increase: 4.4 L/min Sheath size: 23 F

Tandem Heart OSPEDALE The Tandem Heart is a continuous-flow centrifugal assist device placed outside the body (extracorporeally). Cannulas are inserted percutaneously through the femoral vein and advanced across the intra atrial septum into the left atrium. The pump withdraws oxygenated blood from the left atrium, propels it by a magnetically driven, six-bladed impeller through the outflow port, and returns it to one or both femoral arteries via arterial cannulas. The pump is capable of delivering blood flow up to 5.0 liters per minute.

Randomized study of Tandem Heart vs. IABP in 41 pts. No mortality difference, more bleeding events with Tandem Heart (EHJ 2005) Randomized study of Impella vs. IABP in 25 pts. Better hemodynamics with Impella, no mortality difference (JACC 2008)

ECMO Venous canula: 19-25 F Arterial canula: 15-23 F OSPEDALE A large number of studies Mortality range from 25-60% quite high complication rates

3.Myocardial performance LV Shock (PVC<14, PCWP>18) First line IMPELLA 2.5/CP Second line + ECMO (IMPELLA 5.0) RV Shock (PVC>14, PCWP<18) First line IMPELLA RP Second line e/o Hypoxia* ECMO Biventricular Shock (PVC>14, PCWP>18) Hypoxia* ECMO + IABP NON Hypoxia* ECMO o BI-IMPELLA (CP/5.0 + RP) * Hypoxia: PaO2<55 con FiO2 100%

Rescue Mitraclip Implantation in the unstable patient with prohibitive surgical risk following Acute ST Elevation Myocardial Infarction

CVI M&M OSPEDALE

MR: Pre & Post OSPEDALE

HEMODYNAMICS: Pre & Post OSPEDALE Pre MitraClip Post MitraClip

CLINICAL COURSE OSPEDALE Did well post procedure and was discharged 7 days later. Doing well on 4 week and 6 month follow up in valve clinic.

CABG for Cardiogenic Shock OSPEDALE Pooled data from 370 pts. in 22 studies Hospital mortality 36% (JACC 1999) Retrospective analysis in Shock Trial 128 pts. PCI vs. CABG (47 pts.) 30 day mortality CABG 57% PCI 56%

Fibrinolysis is still an option when PCI delay is over 60 min The benefits of fibrinolysis decrease as the delay from symptoms onset to fibrinolysis increase. Side effects related to bleeding stay the same

Conclusions OSPEDALE Early reperfusion is the most important element Hemodynamic support with Impella, Tandem Heart, ECMO should be considered at an early stage Correction of severe mitral regurgitation with MitraClip should be considered